Get informed when a big investor buys or sells
+ FollowOvervalued by 98.8% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $4.28 Million |
|---|---|
| Enterprise Value | $-450,669,148.00 |
| Earnings per Share | $-7.07 |
| Beta | 1.84 |
| Outstanding Shares | 135,256 |
| P/E Ratio | -0.09 |
|---|---|
| PEG | 0 |
| Price to Sales | 4.52 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | -299.3 |
| Enterprise Value to EBIT | 5.67 |
| Enterprise Value to Net Income | 8 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of human therapeutics. Its product pipeline includes several sGC stimulators, small molecules ...